Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
NeoMET Study in Neoadjuvant Treatment of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 92
- Registration Number
- NCT01929811
- Locations
- 🇨🇳
Linyi People's Hospital, Linyi, Shandong, China
🇨🇳Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Phase II Trial for Large ER-Negative Breast Cancers
- Conditions
- Interventions
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 72
- Registration Number
- NCT01869192
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Yale University
- Target Recruit Count
- 50
- Registration Number
- NCT01855828
- Locations
- 🇺🇸
Yale University Smilow Cancer Hospital, New Haven, Connecticut, United States
Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Centre Hospitalier Universitaire de Besancon
- Target Recruit Count
- 30
- Registration Number
- NCT01830270
- Locations
- 🇫🇷
Hospital of Belfort-Montbeliard, Montbeliard, France
🇫🇷University hospital of Besançon, Besançon, France
🇫🇷FNLCC center Georges François Leclerc, Dijon, France
ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 4936
- Registration Number
- NCT01779206
- Locations
- 🇩🇪
Ev. Krankenhaus Bethesda Brustzentrum Niederrhein, Mönchengladbach, NRW, Germany
🇩🇪Breast Center of the University of Munich (LMU) Universitätsfrauenklinik Großhadern, Munich, Bavaria, Germany
Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells
- Conditions
- Interventions
- First Posted Date
- 2013-01-29
- Last Posted Date
- 2022-11-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 7
- Registration Number
- NCT01779050
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 48
- Registration Number
- NCT01740271
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)
- Conditions
- Interventions
- First Posted Date
- 2012-11-15
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 377
- Registration Number
- NCT01726452
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Box 279(s4), Cambridge Biomedical Camp, Cambridge, United Kingdom
🇸🇪Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
🇬🇧Nottingham City Hospital, Nottingham University Hospitals NHS Trust, Hucknall Road, Nottingham, United Kingdom
A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-19
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 35
- Registration Number
- NCT01710592
- Locations
- 🇮🇪
Mercy University Hospital, Cork, Ireland
🇮🇪Beaumont Hospital, Dublin, Ireland
🇮🇪Mater Misericordiae University hospital & Mater Private Hospital, Dublin, Ireland
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 609
- Registration Number
- NCT01697072
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.